Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00062894 · ClinicalTrials.gov registry record · Phase 1
Study of Untreated or Transformed Follicular Non-Hodgkin's Lymphoma With Fission-Derived Iodine I 131 Tositumomab
A Phase 1 study of Non-Hodgkin's Lymphoma, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
- 6
- Study locations
NCT00062894 is a Phase 1 study of Non-Hodgkin's Lymphoma that has completed, run by GlaxoSmithKline. The registered enrollment target is 12 participants, below the 222-participant average among 63 other Non-Hodgkin's Lymphoma trials with a reported enrollment target (95% lower). The trial reports 6 study locations across 6 states.
The verdict
NCT00062894, a Phase 1 study of Non-Hodgkin's Lymphoma, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
- 6
- Study locations
Study Summary
The purpose of this study is to assess the blood pharmacokinetics in patients with previously untreated or relapsed follicular or transformed follicular non-Hodgkin's lymphoma who have received a dosimetric dose of fission-derived iodine I 131 tositumomab.
Conditions Studied
Interventions
- DRUG Iodine I 131 Tositumomab
Study Locations (6)
Florida
- Bay Pines VA Medical Center - Bay Pines
Illinois
- Rush Medical Center - Chicago
Michigan
- University of Michigan Medical Center - Ann Arbor
Nebraska
- University of Nebraska Medical Center - Omaha
North Carolina
- Duke University Medical Center - Durham
Pennsylvania
- Hospital of the University of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2003-04 |
| Est. Completion | 2007-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00062894
The ClinicalTrials.gov registry entry for NCT00062894 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 222-participant average among 63 other Non-Hodgkin's Lymphoma trials with a reported enrollment target (95% lower). The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Non-Hodgkin's Lymphoma appearing as the primary indexed condition, and to 1 intervention - of which Iodine I 131 Tositumomab is the first listed.
NCT00062894 reports 6 study locations spanning 6 distinct geographic areas - top geographies include Florida, Illinois, Michigan.
Frequently Asked Questions
What is clinical trial NCT00062894 about?
NCT00062894 is a clinical study titled "Study of Untreated or Transformed Follicular Non-Hodgkin's Lymphoma With Fission-Derived Iodine I 131 Tositumomab". The purpose of this study is to assess the blood pharmacokinetics in patients with previously untreated or relapsed follicular or transformed follicular non-Hodgkin's lymphoma who have received a dosimetric dose of fission-derived iodine I 131 tositumomab.
What is the current status of trial NCT00062894?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2003-04. Estimated completion is 2007-04.
What conditions does trial NCT00062894 study?
This clinical trial studies the following conditions: Non-Hodgkin's Lymphoma.
What interventions are being tested in trial NCT00062894?
The interventions under investigation include: Iodine I 131 Tositumomab (DRUG).
Who is sponsoring clinical trial NCT00062894?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00062894 being conducted?
This trial has 6 study locations across Florida, Illinois, Michigan, Nebraska, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Hodgkin's Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study to Evaluate Adverse Events and Change in Disease Activity in Adult Participants With B-Cell Malignancies Receiving Oral ABBV-525 Tablets
RECRUITING · Phase 1
-
Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE
RECRUITING · Phase 1
-
A Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-cell Non-hodgkin's Lymphoma
RECRUITING · Phase 1
-
Study to Evaluate Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-291 Moves Through the Body in Adult Participants With Non-Hodgkin's Lymphoma
RECRUITING · Phase 1
-
T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)
RECRUITING · Phase 1
-
Activated T Lymphocytes Expressing CARs, Relapsed CD19+ Malignancies Post-Allo HSCT(CARPASCIO)
ACTIVE NOT RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.